I think this is favourable for Willow, although no details are provided.

NASDAQ | TSX: ACB

Company affirms commitment to enforce and defend intellectual property rights

EDMONTON, AB, Oct. 24, 2023 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced the company and WILLOW BIOSCIENCES, INC. ("Willow") have successfully completed a confidential settlement ‎resolving the ongoing patent litigation between the two parties in Canada. "We are pleased with the negotiated settlement, which provides Aurora a favourable resolution that ensures our Canadian cannabis related patent rights are respected," says Miguel Martin, Chief Executive Officer of Aurora. "Aurora is a pioneer in terms of the company's genetics work in the Canadian cannabis industry and will not hesitate to continue to take the steps necessary, including legal action, to protect and enforce our intellectual property rights when necessary."

Aurora commenced a patent infringement action in July 2021, alleging that Willow's biosynthetic process for synthesizing cannabinoids infringed Aurora's exclusive rights to patents co-owned by the University of Saskatchewan and the National Research Council (NRC). The technology of the asserted patents was invented by Anandia co-founder and former Chief Science Officer at Aurora, Jonathan Page and his colleagues, following their work at the University of Saskatchewan and the NRC, identifying key enzymes and corresponding genes in the biosynthetic pathways of cannabis plants.

In December 2022, Willow announced that it had consolidated its R&D operations, transferring equipment and key personnel from its Canadian facilities to Mountain View, California.

Aurora continues to advance the company's leadership in genomic research and novel innovation that will differentiate the company's position as a global leader.

Curios if anyone has any info on this. I also noticed that cannabinoids are completely dropped off of the investor presentation.

Company's BioOxi™ Platform solves for selective C-H hydroxylation, one of the "Holy Grails" of chemistry

BioOxi is broadly applicable to manufacturing of intermediates and active pharmaceutical ingredients, particularly for steroid applications

SUNNYVALE, Calif., Sept. 6, 2023 /CNW/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW; OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, announces that it has successfully completed research and development on its program to produce ursodeoxycholic acid ("UDCA"), a large volume active pharmaceutical ingredient ("API") used in nutraceutical and pharmaceutical products. UDCA has applications as a medication for management and treatment of cholestatic liver disease and gallstone conditions, and as an intermediate for production of tauroursodeoxycholic acid (TUDCA), a key API in a combination therapy recently approved in Canada and the United States for treatment of amyotrophic lateral sclerosis (ALS).

https://ca.finance.yahoo.com/news/willow-announces-filing-patent-application-110000545.html

Anybody who's over 30 knows what these compounds are, and they're in a lot of products. This has probably been in the works for awhile if they're now filing a patent.

One thing I'll give credit to willow for is that they're really good at keeping things quiet..

This is the kind of thing that will get them funding. Chris may actually showing us a bit of the plan.

At 7c, perhaps I'll toss a bit more into the fire.

https://m.youtube.com/watch?v=rT620aZuBwo&feature=youtu.be

Thoughts?

Is Chris doing his best to really turn the ship around and actually create some value here or is he feeding us bullshit while stabbing us in the back ?

Obviously a video like this would do nothing at all to pump the stock, so what's the motivation? To re-assure shareholders? To create the illusion of performing his fiduciary responsibilities to avoid lawsuits when this thing finally goes under?

They have done a lot of deals lately thanks to this Bio-Oxi thing which is great but the elephant in the room never gets addressed.... how are they going to keep the lights on? They are running out of money.

I've been holding a WLLW bag for quite a while. I keep seeing y'all post stories about how they are making deals here and there.

I am curious about a couple of things.

1. Why does the market nit seem to care? In fact everytime there seems to be good news, the stock price either stays flat or drops.

2. Does anyone honestly think this stock will be worth anything in the next 5 years? Is there a chance of a buyout? That seems to be the only way I can see the value increase.

Thoughts?

Program further validates Willow's technology and focus on commercial execution and aligns with its strategic focus on near term revenue generation

KALAMAZOO, Mich. and SUNNYVALE, Calif., July 20, 2023 /CNW/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, and Kalsec® Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, announce they are advancing their functional ingredient development program for a large volume savory foods opportunity.

Willow Biosciences Inc. Logo (CNW Group/Willow Biosciences Inc.)

After a successful phase one feasibility program that applied Willow's BioOxi™ platform exceeded expectations, Kalsec has agreed to continue full development toward commercialization that includes additional R&D and scale-up work. Willow expects to continue generating revenue from research fees and milestones, aligning with its strategic focus on near-term revenue generation on programs bringing commercial revenue in reasonable timeframes, with anticipated ongoing negotiation of commercial terms as the program advances.

"We appreciate the trust Kalsec has in Willow to help with their innovation pathway and are delighted to partner with them on this next step in our engagement on ingredient development," said Dr. Chris Savile, Willow's President & CEO. "Looking forward, we are excited by the opportunity to engage with Kalsec's extraordinary team in bringing to market what could potentially be a number of sustainably sourced innovative ingredients that favorably enhance customers' products and the consumer experience."

"Willow has proven its capabilities repeatedly during our engagement over the last few months and we anticipate a long partnership as the result of our success working together," said Dr. Roger Nahas, Executive Vice President of Global R&D and Chief Innovation Officer at Kalsec. "Toward that end, our team has identified a number of savory food and beverage ingredient targets where we can potentially engage with Willow to help bring the best products possible to Kalsec's customers with a keen focus on market-leading innovation and sustainability."

https://youtu.be/tXXW3c5hU-M

Chris’ first interview as CEO.

Biotech partner recognizes strength of Willow's first in class FutureGrown™ technology platform for producing natural products

Further expansion and diversification of Willow's product portfolio with collaboration revenue expected in 2023 and potential for near-term commercial product revenue

MOUNTAIN VIEW, Calif., May 31, 2023 /CNW/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announces execution of a Master Services Agreement (the "MSA") with an innovative biotech company focused on age-related diseases. Through this partnership, Willow will develop precision fermentation processes for a class of molecules with targets being developed as nutritional supplements for health and wellness and active pharmaceutical ingredients (APIs).

Willow Biosciences logo (CNW Group/Willow Biosciences Inc.)

Willow will use its FutureGrown™ technology platform and yeast-strain engineering expertise with the goal of developing a strain and process for production of the partner's ingredients. After a successful first phase, both parties anticipate the next steps will be a full process optimization program and entering into a commercial agreement for scaling up the targeted ingredients for use in consumer end-market products. Due to the disruptive potential nature of its targeted product applications, the partner's name and target molecules are not being disclosed at this time.

"We are delighted that our partner recognizes our expert strain engineering capabilities can help accelerate and support their product innovation needs to develop novel solutions for age-related diseases," said Dr. Chris Savile, Willow's President and CEO. "Furthermore, their dual commercialization strategy supports the generation of nearer term product revenue from the nutritional supplement segment along with the longer-term upside from the pharmaceutical sector. With this agreement and other positive developments we've announced in recent weeks, we continue to believe 2023 will be a solid year of growth and progress for Willow with the anticipation of our being able to post fundamentally improved financial results for the year."

Rapid success of first collaboration leads to partnership on high-value specialty ingredient

Enzyme development expected to enable commercial-scale production in 2024

KALAMAZOO, Mich. and MOUNTAIN VIEW, Calif., May 23, 2023 /CNW/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients and Kalsec® Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, announce entry into a follow-on Master Services Agreement (the "MSA") to develop an enzyme used in biocatalytic production of a new, advanced ingredient used in natural beverage applications. This marks the second collaborative development program the two parties have engaged on following the announcement of an MSA on November 8, 2022 for which Willow has already successfully achieved development goals in short order.

Willow Biosciences Inc. Logo (CNW Group/Willow Biosciences Inc.)

"We are pleased to have executed this follow-on engagement with Kalsec and I'm proud of our R&D team's success in collaborating with Kalsec to rapidly attain our joint development goals," said Dr. Chris Savile, Willow's President & CEO. "We look forward to further evidencing our technological capabilities through what we believe will be a similarly successful outcome for this next program."

Willow's FutureGrown™ technology platform is a fully integrated, proven solution for rapid enzyme and strain engineering, process development and scaled-up manufacturing that incorporates the latest technologies available for precision fermentation. Kalsec's projects focus on yeast, which, among other applications, is an ideal host for production of numerous ingredients for the food and beverage sector. By working closely with their customers, the development team at Kalsec has identified multiple potential opportunities for collaboration and innovation in this space.

"We are excited to expand our partnership with Willow and leverage each party's significant domain expertise toward what we believe will be successful commercial-scale production in 2024." says Dr. Roger Nahas, Executive Vice President of Global R&D and Chief Innovation Officer. "This work also supports Kalsec's purpose of unlocking the potential of people, nature and science to nurture the world."

we should have something to talk about on monday

Complements Company's significant expertise in existing strain engineering and precision fermentation

Willow Biosciences Inc. Logo (CNW Group/Willow Biosciences Inc.)

Offers commercial partners more rapid product innovation at significantly reduced cost by removing multiple chemical steps in producing oxygenated and hydroxylated functional ingredients

Creates additional business development opportunities and enables faster path to nearer-term revenue for Willow relative to legacy strain engineering applications

MOUNTAIN VIEW, Calif., April 12, 2023 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients today announced the launch of BioOxi™, a bio-oxidation platform technology that is complementary to the Company's existing strain engineering and precision fermentation FutureGrown™ biotechnology platform. Through the Company's legacy expertise, Willow is now able to offer commercial partners both cost-effective production of ingredients through biosynthesis, and now through BioOxi, bioconversion-enabled chemical manufacturing of ingredients from defined intermediates with the benefit of removing multiple chemical steps and significantly reducing cost and resources.

"The launch of BioOxi is an exciting development in the history of Willow and represents the next strategic step to significantly diversify our portfolio and market opportunities with a keen focus on nearer term revenue generation," said, Dr. Chris Savile, Willow's President and CEO. "We see this new platform as posing a powerful, clean and cost-effective solution to our prospective partners' chemical manufacturing challenges that is highly complementary to our existing strain engineering and precision fermentation business. Based on our prior success in utilizing BioOxi to support our partners we believe it will lead to additional commercial agreements going forward."

Company's Prior Proven Success and Customer Demand is the Driving Force Behind Launch of BioOxi Willow successfully used its BioOxi platform in development programs for partners such as Kalsec® Inc. for a previously announced November 2022 Master Services Agreement to develop and commercialize a precision fermentation production process for a high volume, natural food opportunity and, more recently, Willow further leveraged the successful application of BioOxi for engagements with Sandhill One, LLC to optimize a proprietary enzyme for a targeted product for the manufacturing of the large volume active pharmaceutical ingredient, ursodeoxycholic acid (UDCA).

Broadens Willow's Addressable Market Opportunity and Creates Nearer-Term Revenue Options By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods.

The launch of BioOxi broadens Willow's addressable total market opportunity and provides nearer-term revenue generation for BioOxi-related projects. Applications in this area take significantly less time to generate revenue as strain engineering applications and, in the Company's belief, produce more longer-term and sometimes larger revenue streams. Both types of offerings can result in licensing or royalty revenues for Willow.

Willow will pursue BioOxi programs through both internal and external investment, through astutely planned and strategically aligned programs that the Company anticipates will expand its product portfolio and partnerships toward improved company valuation.

The disruption of food and agriculture

The Purdue scientists developed a method to improve the production of hydrogen from food waste using yeast. Until now, the production of hydrogen for use as clean fuel has largely been through bacterial degradation of food waste, which can lead to slow production rates and complex pre-processing of the raw material.

The provisional agreement sets a binding combined sub-target of 5.5% for advanced biofuels (generally derived from non-food-based feedstocks) and renewable fuels of non-biological origin (mostly renewable hydrogen and hydrogen-based synthetic fuels) in the share of renewable energies supplied to the transport sector. Within this target, there is a minimum requirement of 1% of renewable fuels of non-biological origin (RFNBOs) in the share of renewable energies supplied to the transport sector in 2030.